Series B · Biotech
Superluminal Medicines raises $60M Series B for GPCR drug discovery
Its pipeline focuses on endocrine and cardiometabolic disease, including forms of obesity.
Finding molecules for hard-to-target receptors
Superluminal’s Hyperloop platform combines GPCR structural models, AI-driven molecule design, large-scale screening, ADMET prediction and experimental validation. The workflow is designed to search changing receptor structures and identify small molecules that conventional discovery methods can miss.
The company is advancing its own programs in endocrine and cardiometabolic disease while also working with pharmaceutical partners. Its medicines remain in development rather than available treatments.
Use of funds
Advance lead programs for rare genetic and hypothalamic obesity
Advance pipeline programs
Expand GPCR-targeted small-molecule therapies
Funding history
Series B · This round$60M